Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 17NIH 4INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 2Endocrine 2NET 1CNS 1

Conditions

Thyroid Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Differentiated Thyroid Cancer 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Iodine-131 × Clear all
NCT04964284 2023-10-23

Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Unknown
328 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00196729 2015-03-18

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

Sanofi

Phase 3 Completed
63 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡